132 results about "Oxaliplatin" patented technology

The invention belongs to the technical field of microorganisms, and particularly relates to application of parabacteroides dielsii SYSU-210 and metabolites thereof in cancer treatment. The parabacteroides dieldrii is a parabacteroides dieldrii SYSU-210 strain, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.32494, and the preservation date is November 04, 2024. According to the application disclosed by the invention, by carrying out anti-tumor treatment on tumor-bearing mice with colon cancer and breast cancer by using the single parabacteroides dieldrii SYSU-210 and a metabolite thereof, the screened SYSU-210 has a good treatment effect on both the colon cancer and the breast cancer, and effector T cell infiltration in tumors of the mice in a treatment group is remarkably increased; and when the compound is combined with an immunotherapy alpha PD-1 inhibitor or a chemotherapeutic drug oxaliplatin for use, the effect of synergistically enhancing the curative effect is shown.

The invention discloses application of a target protein circPIAS1-108aa inhibitor combined with oxaliplatin in preparation of a medicine synergistic composition for treating cancers, the specific action mechanism of circPIAS1-108aa in colon cancer treatment is found for the first time, and further research shows that by using siRNA to knock down circPIAS1-108aa, colon cancer cell proliferation can be remarkably inhibited, and the effect of treating the colon cancer can be achieved. Furthermore, the target spot protein circPIAS1-108aa inhibitor can be used for enhancing the treatment effect of the oxaliplatin. Therefore, when the circPIAS1-108aa expression is inhibited in a targeted manner and the oxaliplatin is combined for use, the circPIAS1-108aa can be obviously used for preventing and treating cancers, the dosage and toxic and side effects of the oxaliplatin are reduced, and a new synergistic strategy is provided for tumor treatment.

The invention is applicable to the technical field of biological medicines, provides application of a natural compound of a targeted colon cancer drug resistance related protein, and particularly relates to application in preparation of drugs for preventing or treating colon cancer. According to the invention, a natural small molecule compound neohesperidin dihydrochalcone targeting the colon cancer drug resistance related protein TAGLN is screened out, and a new scheme is provided for reversing colon cancer drug resistance, so that the situation that no drug is available to the target spot is solved. Secondly, the invention also provides a scheme for combined use of neohesperidin dihydrochalcone and oxaliplatin, the scheme can significantly enhance the killing effect of oxaliplatin on drug-resistant colon cancer, and a new choice is provided for clinical treatment of colon cancer.

The present application relates to a kind of pH / H2O2 dual-response drug-loaded hydrogel and its preparation method and application, by ε-polylysine derivative as antitumor active ingredient, with oxidized dextran through Schiff base reaction crosslinking rapid gelation. While using 2-formylphenyl boronic acid covalently package CD73 small molecule inhibitor APCP. ε-polylysine derivative has oncolytic activity, can induce ICD and promote the infiltration of immune cells in tumor cells. CD73 small molecule inhibitor APCP can block extracellular CD39-CD73-adenosine pathway, reduce the level of immunosuppressive metabolite adenosine in tumor tissue, so as to activate the infiltrated immune cells, restore its anti-tumor function. The hydrogel of ε-polylysine derivative and APCP co-delivery synergistically inhibits the effect of tumor growth, and its curative effect is greater than the treatment effect of single drug, and is superior to positive control drug oxaliplatin (OXA). The pH / H2O2 dual-response hydrogel is rapidly gelled, and has good biological safety under mild reaction conditions.

The invention discloses a method for predicting peripheral neurotoxicity induced by treatment of colorectal cancer through oxaliplatin, and relates to the technical field of drug application, and the method comprises the following steps: obtaining pre-drug patient information before treatment of a patient with oxaliplatin and clinical feature data after use; processing and feature analysis are carried out based on pre-drug patient information and clinical feature data, and a core feature data set related to neurotoxin is determined; and based on the core feature data set, predicting the oxaliplatin-induced peripheral neurotoxicity of the patient by adopting a pre-trained gradient boosting decision tree model, and outputting a prediction risk result. According to the method, the occurrence risk of peripheral neurotoxicity can be accurately predicted according to clinical indexes so as to guide clinical accurate medication.

The invention discloses application of circFAM126A in preparation of a medicine for reversing oxaliplatin resistance of gastric cancer, and belongs to the technical field of molecular biology. According to the application disclosed by the invention, by constructing a lentivirus for targeted interference of novel circFAM126A and transfecting gastric cancer cells, it is proved that the lentivirus carrying a specific interference sequence can stably knock down circFAM126A expression in the gastric cancer cells, the drug resistance of the gastric cancer cells to oxaliplatin is effectively reversed, the tumor cell death effect induced by chemotherapeutic drugs is remarkably enhanced, and the tumor cell death effect is remarkably improved. Meanwhile, the proliferation and clone formation capability of gastric cancer cells is inhibited. Meanwhile, it is found that circFAM126A is highly expressed in oxaliplatin-resistant gastric cancer cells and is in positive correlation with poor prognosis of gastric cancer patients, a detection reagent aiming at circFAM126A can be used for auxiliary diagnosis of gastric cancer prognosis conditions, and the drug resistance degree of the gastric cancer cells to oxaliplatin can be evaluated by detecting the expression level of circFAM126A.

This invention discloses a composite nanozyme that enhances the clinical efficacy of oxaliplatin, its preparation method, and its application. The composite nanozyme consists of indium ruthenium nanozyme and an iliximab embedding and anchoring layer. The indium ruthenium nanozyme consists of indium ruthenium nanoparticles and a carbon-nitrogen framework, with the indium ruthenium nanoparticles loaded on the surface and within the pores of the carbon-nitrogen framework. The iliximab embedding and anchoring layer consists of a dithiol polyethylene glycol coating layer and iliximab. Preparation method: ZIF-8 is prepared by co-precipitation of zinc salt methanol solution and 2-methylimidazole methanol solution, followed by calcination to obtain the carbon-nitrogen framework. The carbon-nitrogen framework dispersion is then stirred in an oil bath with indium nitrate solution and ruthenium trichloride solution to prepare a nanozyme precursor, followed by calcination to obtain indium ruthenium nanozyme. The indium ruthenium nanozyme is dispersed in a dithiol polyethylene glycol solution, and iliximab solution is added dropwise. The resulting solid product is then dried. This invention can solve problems such as strong drug tolerance, insufficient intracellular accumulation, and severe tumor immunosuppression in oxaliplatin treatment.

The present invention relates to methods of treating B-cell proliferative disorders, e.g., primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL), by administering glofitamab in combination with gemcitabine and oxaliplatin. Further the invention related to an optimized corticosteroid prophylaxis for glofitamab resulting in lower incidence of cytokine release syndrome (CRS).

The application belongs to the technical field of biological medicine, and provides application of a natural compound targeting colon cancer drug resistance related protein, in particular, application in preparation of a drug for preventing or treating colon cancer; the application screens out a natural small-molecule compound hesperetin dihydrochalcone targeting colon cancer drug resistance related protein TAGLN, and provides a new scheme for reversing colon cancer drug resistance, so as to solve the situation that no drug is available for the target point. In addition, the application further provides a scheme in which hesperetin dihydrochalcone is combined with oxaliplatin, and the scheme can significantly enhance the killing effect of oxaliplatin on drug-resistant colon cancer, thereby providing a new choice for clinical treatment of colon cancer.

The invention discloses an application of a combination of Molephantin and a platinum chemotherapeutic drug in preparation of a drug for treating nasopharynx cancer. The purpose of the invention is to show the pharmaceutical application of Molephantin in tumor growth resistance. In-vitro and in-vivo experiments are combined, and the result shows that the growth of nasopharyngeal carcinoma can be inhibited by combining the Molephantin with the cis-platinum and the oxaliplatin. The invention provides a new application of the combination of the Molephantin and the cis-platinum, and provides a new drug source for adjuvant therapy of cancers.

The invention belongs to the technical field of biological medicine, and particularly provides application of a PLA1A gene / protein as an anti-tumor target. The key effect of the PLA1A gene / protein in promoting chemotherapy drug resistance is disclosed for the first time, and a new mechanism that the PLA1A gene / protein affects chemotherapy sensitivity by regulating a tumor microenvironment (especially macrophage polarization) is deeply clarified. Researches prove that knockdown of the PLA1A gene or inhibition of the protein activity of the PLA1A gene can significantly enhance the sensitivity of tumor cells to chemotherapeutic drugs (such as oxaliplatin), so that the therapeutic effect is improved, and the sensitization provides a new strategy for overcoming tumor chemotherapeutic drug resistance. In animal model experiments, knockdown of the PLA1A is combined with oxaliplatin for treatment, so that growth of mouse transplanted tumors and liver metastases is remarkably inhibited, the survival time of tumor-bearing mice is prolonged, and it is indicated that the PLA1A has important clinical application value and wide application prospects as an anti-tumor target.

This invention discloses a composite nanodelivery system encapsulated in a fusion membrane, its preparation method, and its applications. The nanodelivery system comprises a Ti3C2 / TiO2 / CuInS2 composite material, oxaliplatin loaded thereon, and a fusion membrane encapsulating the outer layer; the fusion membrane is formed by the fusion of Fusobacterium nucleatum extravesicles and M1 macrophage membranes. This invention also discloses a method for preparing the nanodelivery system, including the steps of preparing the Ti3C2 / TiO2 / CuInS2 composite material, preparing the fusion membrane, loading oxaliplatin, and encapsulating it in the fusion membrane. The nanodelivery system prepared by this invention exhibits pH-responsive drug release characteristics, generating H2S in the tumor microenvironment and H2 under light irradiation, while also possessing photocatalytic activity. This invention combines chemotherapy, photoelectrocatalytic therapy, and the regulation of multiple active substances, and can be used to prepare drugs for treating malignant tumors of the digestive system.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a series of 15-membered ring quadruple lactone derivatives with neoantimycin mother nucleus structures, a preparation method of the 15-membered ring quadruple lactone derivatives and application of the 15-membered ring quadruple lactone derivatives in antitumor drugs, wherein the 15-membered ring quadruple lactone derivatives are generated by feeding chemical precursors in the fermentation process of streptomyces S.conglobatusATCC 31005. The compound is a fifteen-membered ring quadruple lactone derivative, the C-2 position of the derivative is connected with a carbonyl group or a hydroxyl group, the C-4 position and the C-9 position are substituted by aliphatic chains with different lengths, and the C-6 position of the derivative is connected with a benzoic acid group containing F atoms or hydroxyl groups. The compounds have obvious tumor cell proliferation inhibition activity on colorectal cancer cells and lung cancer cells, the inhibition activity is equivalent to that of a control drug oxaliplatin, and the compounds have weak toxicity on non-cancer cell strains. A novel lead compound is provided for research and development of novel antitumor drugs, and the compound is expected to be developed into a tumor inhibitor.

The invention belongs to the technical field of biomedicine, and particularly relates to application of SOX4 in preparation of a preparation for improving sensitivity of cervical cancer to chemotherapeutic drugs, and the amino acid sequence of the SOX4 is as shown in SEQ ID NO.1. An SOX4 knocked-down stable transfection cell line is constructed in a Hela cell, then carboplatin and oxaliplatin are respectively added into the SOX4 knocked-down Hela cell, and the IC50 of the cell to the carboplatin and the oxaliplatin is obviously reduced, which indicates that the sensitivity of the Hela cell to the carboplatin and the oxaliplatin is enhanced by SOX4 knock-down. By reducing the expression of SOX4, the sensitivity of Hela cells to chemotherapeutic drugs such as carboplatin and oxaliplatin is enhanced, so that the treatment effect of the chemotherapeutic drugs such as carboplatin and oxaliplatin is effectively improved. Results of the invention prove that inhibition of SOX4 is beneficial to recovery of chemosensitivity of cervical cancer cells to drugs such as carboplatin and oxaliplatin, and a new treatment strategy is provided for treatment of drug-resistant cervical cancer.

The invention discloses an application of indoleacetic acid in preparation of a medicine for preventing or treating neuropathic toxicity caused by chemotherapeutics. Experimental results show that the indoleacetic acid (IAA) can significantly relieve pain sensitivity of mice caused by neuropathic toxicity (OIPN) caused by oxaliplatin (OXA), improve morphological damage of dorsal root ganglion (DRG) of the mice and reduce the inflammation level in colon of the mice; however, these benefits are significantly blocked when antagonists are used for the aromatic hydrocarbon receptor (AhR). This indicates that the therapeutic effect of IAA may depend on the activation of the aromatic hydrocarbon receptor (AhR) pathway. The invention provides a new method for treating neuropathic toxicity caused by chemotherapeutics, and expands the application of indoleacetic acid at the same time.

The invention provides application of combined use of ophiopogonin D and oxaliplatin in preparation of a medicine for treating colorectal cancer. The invention also provides a nano-drug delivery system containing co-assembly of ophiopogonin D and oxaliplatin, and the nano-drug delivery system is prepared by the following steps: by taking ZIF-8, ophiopogonin D and oxaliplatin as raw materials, synthesizing ZIF-8 (at) OPHamp, taking the ZIF-8 (at) OPHamp as a carrier, and taking the ZIF-8 (at) OPHamp as a carrier to prepare the nano-drug delivery system containing co-assembly of ophiopogonin D and oxaliplatin. The invention relates to an OXA nanoparticle (ZOX NPs). The invention also provides a co-assembled nano-drug delivery system containing the hyaluronic acid. According to the invention, ophiopogonin D and oxaliplatin are co-assembled by using a nano traditional Chinese medicine delivery system, and the nano preparation HZOX NPs is successfully synthesized, so that the drug can be more enriched at a tumor site, and the problems of poor stability, poor water solubility, low bioavailability and the like of ophiopogonin D are solved. The nanoparticles are uniform in particle size, high in stability and good in biocompatibility, the nano traditional Chinese medicine delivery system can resist colorectal cancer chemical resistance, and a promising strategy is provided for colorectal cancer treatment.

The present invention relates to Akkermansia muciniphila and its applications, belonging to the technical field of microbiology. The Akkermansia muciniphila described in the present invention is Akkermansia muciniphila SYSU-85, which was deposited on August 8, 2024 at the General Microbiological Center of the China General Microbiological Culture Collection Center, and its deposit number is: CGMCC NO. 46070. The Akkermansia muciniphila SYSU-85 of the present invention has a weak dependence on mucin, grows well in BHI medium supplemented with cysteine, and is resistant to oxaliplatin. The Akkermansia muciniphila SYSU-85 of the present invention alleviates the adverse reactions caused by oxaliplatin, and in combination with oxaliplatin or PD-1 inhibitor, significantly slows down the tumor growth curve and significantly reduces the tumor volume, improving the tumor treatment effect.

The invention discloses a diphosphonic acid manganese nanoparticle, a preparation method thereof and application of the diphosphonic acid manganese nanoparticle in tumor treatment. The preparation method comprises the following steps: dropwise adding a water-in-oil emulsion system of diphosphonate into a water-in-oil emulsion system of manganese ions in stirring to establish a coordination skeleton, curing by absolute ethyl alcohol, adding a certain proportion of fat material, performing vortex hydration by a film dispersion method, and extruding to pass through a film. The diphosphonic acid manganese nanoparticle is small in particle size and good in stability, and has a pH-sensitive release characteristic; the constructed nanoparticles have a remarkable immune regulation effect, and the ICD effect and the cytotoxic effect of oxaliplatin are enhanced by directly acting on tumor cells. The diphosphonic acid manganese nanoparticles cooperate with Oxp to effectively inhibit digestive tract tumor growth and distal metastatic tumors, the dosage of Oxp can be further reduced, and the diphosphonic acid manganese nanoparticles have good in-vivo safety.

The present application relates to the application of ocanin in the preparation of anti-tumor drugs, and the ocanin is used in the anti-tumor drugs alone or in combination with 5-fluorouracil, and the concentration of the ocanin used in the preparation of anti-intestinal cancer drugs is 20-500 uMol. It is found that the ocanin can inhibit the growth of intestinal cancer cells in vivo and in vitro, and the naked mice have good tolerance to the natural compound. The ocanin has better anti-intestinal cancer effect than other extracts of goldeneye and devil's needle, and has better anti-cancer effect and smaller toxicity than the current conventional intestinal cancer drug 5-fluorouracil. Therefore, the ocanin can be developed into a new anti-cancer drug.

The invention relates to application of an HOXB9 inhibitor in a medicine for reversing oxaliplatin resistance of gastric cancer, and belongs to the field of biological medicine. The invention discloses for the first time: HOXB9 is remarkably high in expression and is positively correlated with poor prognosis in tissues of patients with gastric cancer, which are poor in curative effect after chemotherapy containing oxaliplatin; by constructing an oxaliplatin drug-resistant gastric cancer cell strain and a patient-derived organ model, the HOXB9 is proved to specifically mediate the survival of the drug-resistant cell strain by activating a focal adhesion signaling pathway (p-FAK / AKT), and the HOXB9 is irrelevant to cell proliferation. Aiming at the mechanism, shRNA nucleic acid molecules (SEQ ID NO: 1-2) targeting HOXB9 are provided, and drug-resistant cell strains can be selectively killed through lentiviral vector delivery, so that the drug-resistant cell IC50 is reduced by more than 50%, the apoptosis rate is increased by 3 times, and the chemotherapy resistance of organoids is reversed. The invention provides a brand-new target spot and a treatment scheme for overcoming the drug resistance of oxaliplatin for gastric cancer.

This invention provides biomimetic nanopharmaceuticals for mitochondrial dysfunction, methods for producing the same, and applications. [Solution] The biomimetic nanodrug comprises an RGD-engineered exosome as a carrier, decalinium chloride modified on the surface of the carrier, and oxaliplatin encapsulated inside the carrier. The biomimetic nanodrug of the present invention (OXA@Exo-RD) protects cargoes that induce mitochondrial dysfunction in the blood circulation process, sequentially increasing the accumulation of mitochondria in the cargoes by targeting them. Cargo 1 (DQA) induces oxidative stress, triggering mitochondrial-mediated apoptosis and mitochondrial dysfunction, while cargo 2 (OXA) disrupts mitochondrial DNA and inhibits the initiation of DNA repair, thereby improving chemotherapy resistance. Both cargoes synergistically overcome CRC drug resistance and inhibit its migration.

The application discloses application of pachymic acid B in preparation of a medicine for preventing peritoneal metastasis of gastric cancer and a medicine composition thereof. The pachymic acid B is chemically named as 3-O-acetyl-16alpha-hydroxydehydrotrametenolic acid. The in-situ transplantation peritoneal metastasis model of the gastric cancer proves that intraperitoneal injection of the pachymic acid B can significantly reduce the number of peritoneal metastasis nodules and tumor load, the prevention effect is equivalent to that of oxaliplatin, and there is no obvious organ toxicity. Further experiments prove that the pachymic acid B can up-regulate the mRNA and protein expression levels of SPRED2 genes in peritoneal tissues of the gastric cancer, and plays a role in a time-dose dependent manner. The pachymic acid B provided by the application is administered by intraperitoneal injection, can be prepared into a suspension containing sodium carboxymethyl cellulose, and is especially suitable for perioperative administration of gastric cancer primary focus resection. Compared with the prior art, the application has the advantages of clear composition, novel action mechanism, high safety, simple operation, strong accessibility and the like.

The present application relates to the role of UCK1 in promoting the sensitization of colorectal cancer treatment. The present application discloses the key role of UCK1 in the treatment of colorectal cancer. Clinical samples show that the expression of UCK1 in tumor tissues is reduced, and its low expression is related to chemotherapy resistance and poor prognosis. Studies have shown that UCK1 enhances the efficacy of oxaliplatin (OXA) by regulating metabolic pathways, and promotes B cell activation, thereby recruiting CD8 + T cells, and strengthens anti-tumor immunity. UCK1 overexpression can significantly improve OXA sensitivity and produce a synergistic effect with anti-PD-1 therapy. The present application proposes a new strategy centered on activating UCK1, providing a theoretical basis and application prospect for improving the response of colorectal cancer chemotherapy and immunotherapy.

The application relates to a pharmaceutical application technology, in particular to application of gallic acid in preparation of a medicine for preventing or treating peripheral neuropathy. The peripheral neuropathy is acute peripheral neuropathy caused by using a chemotherapy drug, oxaliplatin. The gallic acid has a protective effect on acute peripheral nerve toxicity of mice induced by oxaliplatin. The medicine, gallic acid, can be used as an adjuvant of a chemotherapy drug for cancer treatment, and has a significant alleviating effect on nerve toxicity caused by chemotherapy.

The invention discloses application of ginsenoside Rg1 in preparation of a product for treating oxaliplatin-induced liver injury, and belongs to the technical field of medicines. Experimental verification shows that after ginsenoside Rg1 is administrated, the survival rate of HL-7702 human hepatocytes induced by oxaliplatin is increased, the content of transaminase indexes AST and ALT in the cells is obviously reduced, the content of active oxygen is obviously reduced, and the condition of mouse liver injury can be obviously improved. The experimental results show that the ginsenoside Rg1 can improve the liver injury induced by oxaliplatin, and a new technical thought is provided for preparing the product for treating the liver injury induced by oxaliplatin.

The invention belongs to the technical field of biological medicine, and particularly relates to application of lovastatin combined with DHCR7 inhibitor AY9944 in preparation of medicine for treating colorectal cancer. The DHCR7 protein expression in the drug-resistant tumor tissue is obviously improved compared with that of normal tumor cells, and verification finds that the DHCR7 inhibitor AY9944 can specifically inhibit the drug resistance of colorectal cancer cells generating drug resistance, and further finds that when AY9944 and lovastatin are combined for use at a specific concentration ratio, the drug resistance of the colorectal cancer cells generating drug resistance can be inhibited, and the drug resistance of the colorectal cancer cells generating drug resistance can be inhibited. The two can play an obvious synergistic effect, so that the sensitivity of intestinal cancer cells to oxaliplatin is more effectively improved. Therefore, the combined medication mode provided by the invention can provide a new strategy reference for clinically overcoming the chemotherapy resistance of colorectal cancer.

The invention belongs to the technical field of biological pharmacy, and particularly relates to polylysine nanoparticles for delivering oxaliplatin and a preparation method of the polylysine nanoparticles. The invention discloses a preparation method of polylysine nanoparticles for delivering oxaliplatin. The polylysine nanoparticles are applied to preparation of a tumor targeting drug mPssPC-OXA NPs with small particle size, positive surface charge and excellent stability. The mPssPC-OXA NPs can respond to a tumor microenvironment with high GSH concentration to quickly release a drug, and shows an excellent HCT-116 cell uptake effect and an effective RAW264.7 cell immune escape effect in an in-vitro anti-colon cancer cell test. In addition, the mPssPC-OXA NPs also shows more remarkable cytotoxicity, cell migration inhibition, cell proliferation inhibition and HCT-116 cell apoptosis induction effects compared with free OXA.

The present invention provides a derivative having a desloratadine tetravalent platinum structure, a preparation method, and a use thereof. The compound having a desloratadine tetravalent platinum structure is shown in general formula (I), #imgabs0# wherein #imgabs1# is selected from cisplatin or oxaliplatin; L is hydroxyl or #imgabs2#. The desloratadine tetravalent platinum compound of the present invention has good anti-tumor proliferation activity and a good therapeutic effect on metastatic malignant tumors; it can effectively inhibit the tumor epithelial-mesenchymal transition (EMT) process and effectively activate tumor immune response, and can be used to prepare anti-tumor drugs, especially providing a new direction for the research and development of anti-metastatic malignant tumor drugs.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a combination of punicalagin and a chemotherapeutic drug oxaliplatin (OXA) in preparation of a drug for treating gastric cancer ovarian metastasis. Researches show that in various animal models of gastric cancer ovarian metastasis of mice, single treatment of oxaliplatin cannot inhibit tumor growth, punicalagin shows a certain effect of inhibiting tumor growth, and punicalagin and oxaliplatin are combined for medication to show significant synergistic interaction and significantly inhibit tumor growth. The pharmaceutical composition is simple in component and can be used for treating gastric cancer ovarian metastasis, especially for patients insensitive to oxaliplatin, and punicalagin and oxaliplatin are both marketed drugs, can be quickly developed and applied clinically and have good popularization and application prospects.

The present invention belongs to the field of pharmaceutical technology, and discloses a febuxostat tetravalent platinum prodrug, a preparation method and a preparation. The present invention synthesizes two small molecule tetravalent platinum prodrugs of tetravalent platinum, febuxostat cisplatin and febuxostat oxaliplatin, for the first time, and prepares a febuxostat cisplatin nanoformulation. The nanoformulation solves the shortcomings of cisplatin such as poor water solubility, congenital or acquired drug resistance, and obvious toxic and side effects, and has many advantages such as passive targeting of tumor tissue. It is not only economical and practical, but also provides possibilities for industrial production. By using the idea of ​​"drug repositioning", the anti-tumor effect of febuxostat is further studied, and a combined anti-tumor effect with platinum drugs is achieved. At the same time, a carrier-free preparation method is adopted to avoid the unknown toxicity of the carrier, the preparation has good safety, and the tumor targeting of platinum drugs is achieved by nanoformulation, while enhancing the accumulation of tumor sites and reducing systemic toxic and side effects.